Role of the Microbiome in Reducing Risk of C diff Recurrence
October 24, 2017
Hosted by Nancy C. Caralla
Join us with our guest Barbara McGovern, MD. Since 2012 Dr. McGovern has been working within the pharmaceutical arena and currently is head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Their lead microbiome therapeutic drug is SER-109, which is being evaluated in a phase 3 clinical trial for recurrent Clostridium difficile infection. We will be discussing the role of the Microbiome in reducing the risk of C. diff. infection recurrence.
C. diff. Spores and More
Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
“C. diff. Spores and More” is an educational program providing you with up-to-date information pertaining to C. diff. and Healthcare-Associated infections. Raising awareness through education and advocacy saves lives worldwide. Topics are of C. difficile infection (CDI) prevention, treatments, and environmental safety products along with Healthcare-Associated Infection (HAI) awareness and more. Our guests are topic experts discussing Antibiotic Resistance, Research and Development, Clinical trials, Nutrition Counseling, Microbiome, Mental health, C. diff. survivors, and so much more. Please join us every Tuesday at 10 AM Pacific Time on the VoiceAmerica Health and Wellness Channel.
Nancy C. Caralla
Nancy C. Caralla, a three time C. diff. survivor, healthcare professional, and now dedicated to “Raising C. diff. Awareness” worldwide. Through the experiences is why we are so passionate raising C. diff. awareness. The C Diff Foundation was brought to fruition in November 2012 with a mission to educate and advocate for C. diff. infection prevention, treatment, and environmental safety worldwide. We now join the many successful hosts and programs on VoiceAmerica to deliver life-saving information through our program; “C. diff. Spores and More.”